Enzyme Catalysis: a New Definition Accounting for Noncovalent Substrate- and Product-Like States
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mito
fnins-12-00402 June 26, 2018 Time: 12:46 # 1 ORIGINAL RESEARCH published: 26 June 2018 doi: 10.3389/fnins.2018.00402 Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mitochondrial Trafficking in Adult Sensory Neurons Mohammad G. Sabbir1*, Nigel A. Calcutt2 and Paul Fernyhough1,3 1 Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada, 2 Department of Pathology, University of California, San Diego, San Diego, CA, United States, 3 Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada The muscarinic acetylcholine type 1 receptor (M1R) is a metabotropic G protein-coupled Edited by: receptor. Knockout of M1R or exposure to selective or specific receptor antagonists Roberto Di Maio, elevates neurite outgrowth in adult sensory neurons and is therapeutic in diverse University of Pittsburgh, United States models of peripheral neuropathy. We tested the hypothesis that endogenous M1R Reviewed by: activation constrained neurite outgrowth via a negative impact on the cytoskeleton Roland Brandt, University of Osnabrück, Germany and subsequent mitochondrial trafficking. We overexpressed M1R in primary cultures Rick Dobrowsky, of adult rat sensory neurons and cell lines and studied the physiological and The University of Kansas, United States molecular consequences related to regulation of cytoskeletal/mitochondrial dynamics *Correspondence: and neurite outgrowth. In adult primary neurons, overexpression of M1R caused Mohammad G. Sabbir disruption of the tubulin, but not actin, cytoskeleton and significantly reduced neurite [email protected] outgrowth. Over-expression of a M1R-DREADD mutant comparatively increased neurite Specialty section: outgrowth suggesting that acetylcholine released from cultured neurons interacts This article was submitted to with M1R to suppress neurite outgrowth. -
Part I Principles of Enzyme Catalysis
j1 Part I Principles of Enzyme Catalysis Enzyme Catalysis in Organic Synthesis, Third Edition. Edited by Karlheinz Drauz, Harald Groger,€ and Oliver May. Ó 2012 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2012 by Wiley-VCH Verlag GmbH & Co. KGaA. j3 1 Introduction – Principles and Historical Landmarks of Enzyme Catalysis in Organic Synthesis Harald Gr€oger and Yasuhisa Asano 1.1 General Remarks Enzyme catalysis in organic synthesis – behind this term stands a technology that today is widely recognized as a first choice opportunity in the preparation of a wide range of chemical compounds. Notably, this is true not only for academic syntheses but also for industrial-scale applications [1]. For numerous molecules the synthetic routes based on enzyme catalysis have turned out to be competitive (and often superior!) compared with classic chemicalaswellaschemocatalyticsynthetic approaches. Thus, enzymatic catalysis is increasingly recognized by organic chemists in both academia and industry as an attractive synthetic tool besides the traditional organic disciplines such as classic synthesis, metal catalysis, and organocatalysis [2]. By means of enzymes a broad range of transformations relevant in organic chemistry can be catalyzed, including, for example, redox reactions, carbon–carbon bond forming reactions, and hydrolytic reactions. Nonetheless, for a long time enzyme catalysis was not realized as a first choice option in organic synthesis. Organic chemists did not use enzymes as catalysts for their envisioned syntheses because of observed (or assumed) disadvantages such as narrow substrate range, limited stability of enzymes under organic reaction conditions, low efficiency when using wild-type strains, and diluted substrate and product solutions, thus leading to non-satisfactory volumetric productivities. -
Insulysin Hydrolyzes Amyloid Β Peptides to Products That Are Neither Neurotoxic Nor Deposit on Amyloid Plaques
The Journal of Neuroscience, December 1, 2000, 20(23):8745–8749 Insulysin Hydrolyzes Amyloid  Peptides to Products That Are Neither Neurotoxic Nor Deposit on Amyloid Plaques Atish Mukherjee,1 Eun-suk Song,1 Muthoni Kihiko-Ehmann,2 Jack P. Goodman Jr,3 Jan St. Pyrek,3 Steven Estus,2 and Louis B. Hersh1 1Department of Biochemistry, 2Department of Physiology and Sanders-Brown Center on Aging, and 3Mass Spectrometry Facility, University of Kentucky, Lexington, Kentucky 40536-0298   Insulysin (EC. 3.4.22.11) has been implicated in the clearance of action of insulysin on A 1–40 and A 1–42 was shown to eliminate  amyloid peptides through hydrolytic cleavage. To further study the neurotoxic effects of these peptides. Insulysin was further   the action of insulysin on A peptides recombinant rat insulysin shown to prevent the deposition of A 1–40 onto a synthetic   was used. Cleavage of both A 1–40 and A 1–42 by the recombi- amyloid. Taken together these results suggest that the use of nant enzyme was shown to initially occur at the His 13-His 14, insulysin to hydrolyze A peptides represents an alternative gene His 14-Gln 15, and Phe 19-Phe 20 bonds. This was followed by a therapeutic approach to the treatment of Alzheimer’s disease. slower cleavage at the Lys 28-Gly 29,Val18-Phe 19, and Phe 20- Ala 21 positions. None of the products appeared to be further Key words: amyloid peptide metabolism; metallopeptidase; metabolized by insulysin. Using a rat cortical cell system, the insulysin; A neurotoxicity; A deposition; A cleavage The major pathological feature of Alzheimer’s disease is the pres- Kurochkin and Goto (1994) showed that another zinc metal- ence of senile plaques in the brain of affected individuals. -
Evidence for Conformational Change-Induced Hydrolysis of Β-Tubulin-GTP
bioRxiv preprint doi: https://doi.org/10.1101/2020.09.08.288019; this version posted September 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Evidence for conformational change-induced hydrolysis of β-tubulin-GTP Mohammadjavad Paydar1 and Benjamin H. Kwok1† 1 Institute for Research in Immunology and Cancer (IRIC), Département de médecine, Université de Montréal, P.O. Box 6128, Station Centre-Ville, Montréal, QC H3C 3J7, Canada. † Corresponding author: B. H. Kwok: [email protected] Keywords: Kinesin, Kif2A, MCAK, motor protein, microtubules, tubulin, GTP hydrolysis Abbreviations NM: Neck+Motor MD: Motor domain MT: Microtubule Running title: Tubulin GTP hydrolysis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.08.288019; this version posted September 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Microtubules, protein polymers of α/β-tubulin dimers, form the structural framework for many essential cellular processes including cell shape formation, intracellular transport, and segregation of chromosomes during cell division. It is known that tubulin-GTP hydrolysis is closely associated with microtubule polymerization dynamics. However, the precise roles of GTP hydrolysis in tubulin polymerization and microtubule depolymerization, and how it is initiated are still not clearly defined. We report here that tubulin-GTP hydrolysis can be triggered by conformational change induced by the depolymerizing kinesin-13 proteins or by the stabilizing chemical agent paclitaxel. We provide biochemical evidence that conformational change precedes tubulin-GTP hydrolysis, confirming this process is mechanically driven and structurally directional. -
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
R&D Assay for Alzheimer's Disease
R&DR&D assayassay forfor Alzheimer’sAlzheimer’s diseasedisease Target screening⳼ Ⲽ㬔 antibody array, ᢜ⭉㬔 ⸽ἐⴐ Amyloid β-peptide Alzheimer’s disease⯸ ኸᷠ᧔ ᆹ⸽ inhibitor, antibody, ELISA kit Surwhrph#Surilohu#Dqwlerg|#Duud| 6OUSFBUFE 1."5SFBUFE )41 $3&# &3, &3, )41 $3&# &3, &3, 壤伡庰䋸TBNQMF ɅH 侴䋸嵄䍴䋸BOBMZUFT䋸䬱娴哜塵 1$ 1$ 1$ 1$ 5IFNPTUSFGFSFODFEBSSBZT 1$ 1$ QQ α 34, .4, 503 Q α 34, .4, 503 %SVHTDSFFOJOH0òUBSHFUFòFDUT0ATHWAY涭廐 6OUSFBUFE 堄币䋸4BNQMF侴䋸8FTUFSOPS&-*4"䍘䧽 1."5SFBUFE P 8FTUFSOCMPU廽喜儤应侴䋸0, Z 4VCTUSBUF -JHIU )31DPOKVHBUFE1BO "OUJQIPTQIPUZSPTJOF .FBO1JYFM%FOTJUZ Y $BQUVSF"OUJCPEZ 5BSHFU"OBMZUF "SSBZ.FNCSBOF $3&# &3, &3, )41 .4, Q α 34, 503 Human XL Cytokine Array kit (ARY022, 102 analytes) Adiponectin,Aggrecan,Angiogenin,Angiopoietin-1,Angiopoietin-2,BAFF,BDNF,Complement,Component C5/C5a,CD14,CD30,CD40L, Chitinase 3-like 1,Complement Factor D,C-Reactive Protein,Cripto-1,Cystatin C,Dkk-1,DPPIV,EGF,EMMPRIN,ENA-78,Endoglin, Fas L,FGF basic,FGF- 7,FGF-19,Flt-3 L,G-CSF,GDF-15,GM-CSF,GRO-α,Grow th Hormone,HGF,ICAM-1,IFN-γ,IGFBP-2,IGFBP-3, IL-1α,IL-1β, IL-1ra,IL-2,IL-3,IL-4,IL- 5,IL-6,IL-8, IL-10,IL-11,IL-12, IL-13,IL-15,IL-16,IL-17A,IL-18 BPa,IL-19,IL-22, IL-23,IL-24,IL-27, IL-31,IL-32α/β/γ,IL-33,IL-34,IP-10,I-TAC,Kallikrein 3,Leptin,LIF,Lipocalin-2,MCP-1,MCP-3,M-CSF,MIF,MIG,MIP-1α/MIP-1β,MIP-3α,MIP-3β,MMP-9, Myeloperoxidase,Osteopontin, p70, PDGF-AA, PDGF-AB/BB,Pentraxin-3, PF4, RAGE, RANTES,RBP4,Relaxin-2, Resistin,SDF-1α,Serpin E1, SHBG, ST2, TARC,TFF3,TfR,TGF- ,Thrombospondin-1,TNF-α, uPAR, VEGF, Vitamin D BP Human Protease (34 analytes) / -
ENZYMES: Catalysis, Kinetics and Mechanisms N
ENZYMES: Catalysis, Kinetics and Mechanisms N. S. Punekar ENZYMES: Catalysis, Kinetics and Mechanisms N. S. Punekar Department of Biosciences & Bioengineering Indian Institute of Technology Bombay Mumbai, Maharashtra, India ISBN 978-981-13-0784-3 ISBN 978-981-13-0785-0 (eBook) https://doi.org/10.1007/978-981-13-0785-0 Library of Congress Control Number: 2018947307 # Springer Nature Singapore Pte Ltd. 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. -
NIH Public Access Author Manuscript Future Neurol
NIH Public Access Author Manuscript Future Neurol. Author manuscript; available in PMC 2013 January 08. Published in final edited form as: Future Neurol. 2012 November 1; 7(6): 749–771. doi:10.2217/FNL.12.68. Opening Pandora’s jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, $watermark-textand $watermark-text central $watermark-text disorders Rajesh Khanna1,2,3,4,*, Sarah M Wilson1,‡, Joel M Brittain1,‡, Jill Weimer5, Rukhsana Sultana6, Allan Butterfield6, and Kenneth Hensley7 1Program in Medical Neurosciences, Paul & Carole Stark Neurosciences Research Institute Indianapolis, IN 46202, USA 2Departments of Pharmacology & Toxicology, Indianapolis, IN 46202, USA 3Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA 4Sophia Therapeutics LLC, Indianapolis, IN 46202, USA 5Sanford Children’s Health Research Center, Sanford Research & Department of Pediatrics, Sanford School of Medicine of the University of South Dakota, Sioux Falls, SD 57104, USA 6Department of Chemistry, Center of Membrane Sciences, & Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506, USA 7Department of Pathology & Department of Neurosciences, University of Toledo Medical Center, Toledo, OH 43614, USA Abstract CRMP2, also known as DPYSL2/DRP2, Unc-33, Ulip or TUC2, is a cytosolic phosphoprotein that mediates axon/dendrite specification and axonal growth. Mapping the CRMP2 interactome has revealed previously unappreciated functions subserved by this -
Exploring the Chemistry and Evolution of the Isomerases
Exploring the chemistry and evolution of the isomerases Sergio Martínez Cuestaa, Syed Asad Rahmana, and Janet M. Thorntona,1 aEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom Edited by Gregory A. Petsko, Weill Cornell Medical College, New York, NY, and approved January 12, 2016 (received for review May 14, 2015) Isomerization reactions are fundamental in biology, and isomers identifier serves as a bridge between biochemical data and ge- usually differ in their biological role and pharmacological effects. nomic sequences allowing the assignment of enzymatic activity to In this study, we have cataloged the isomerization reactions known genes and proteins in the functional annotation of genomes. to occur in biology using a combination of manual and computa- Isomerases represent one of the six EC classes and are subdivided tional approaches. This method provides a robust basis for compar- into six subclasses, 17 sub-subclasses, and 245 EC numbers cor- A ison and clustering of the reactions into classes. Comparing our responding to around 300 biochemical reactions (Fig. 1 ). results with the Enzyme Commission (EC) classification, the standard Although the catalytic mechanisms of isomerases have already approach to represent enzyme function on the basis of the overall been partially investigated (3, 12, 13), with the flood of new data, an integrated overview of the chemistry of isomerization in bi- chemistry of the catalyzed reaction, expands our understanding of ology is timely. This study combines manual examination of the the biochemistry of isomerization. The grouping of reactions in- chemistry and structures of isomerases with recent developments volving stereoisomerism is straightforward with two distinct types cis-trans in the automatic search and comparison of reactions. -
1/05661 1 Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... - 12 May 2011 (12.05.2011) W 2 11/05661 1 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/00 (2006.0 1) C12Q 1/48 (2006.0 1) kind of national protection available): AE, AG, AL, AM, C12Q 1/42 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 10/054171 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 26 October 2010 (26.10.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/255,068 26 October 2009 (26.10.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, MYREXIS, INC. -
Anti-IDE / Insulysin Antibody (ARG57598)
Product datasheet [email protected] ARG57598 Package: 100 μl anti-IDE / Insulysin antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes IDE / Insulysin Tested Reactivity Hu, Ms, Rat Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name IDE / Insulysin Antigen Species Human Immunogen Synthetic peptide derived from Human IDE / Insulysin. Conjugation Un-conjugated Alternate Names Insulysin; Abeta-degrading protease; Insulinase; EC 3.4.24.56; Insulin protease; INSULYSIN; Insulin- degrading enzyme Application Instructions Application table Application Dilution IHC-P 1:50 - 1:100 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 118 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.4), 150mM NaCl, 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol IDE Gene Full Name insulin-degrading enzyme Background This gene encodes a zinc metallopeptidase that degrades intracellular insulin, and thereby terminates insulins activity, as well as participating in intercellular peptide signalling by degrading diverse peptides such as glucagon, amylin, bradykinin, and kallidin. -
Enzyme Catalysis: Structural Basis and Energetics of Catalysis
PHRM 836 September 8, 2015 Enzyme Catalysis: structural basis and energetics of catalysis Devlin, section 10.3 to 10.5 1. Enzyme binding of substrates and other ligands (binding sites, structural mobility) 2. Energe(cs along reac(on coordinate 3. Cofactors 4. Effect of pH on enzyme catalysis Enzyme catalysis: Review Devlin sections 10.6 and 10.7 • Defini(ons of catalysis, transi(on state, ac(vaon energy • Michaelis-Menten equaon – Kine(c parameters in enzyme kine(cs (kcat, kcat/KM, Vmax, etc) – Lineweaver-Burk plot • Transi(on-state stabilizaon • Meaning of proximity, orientaon, strain, and electrostac stabilizaon in enzyme catalysis • General acid/base catalysis • Covalent catalysis 2015, September 8 PHRM 836 - Devlin Ch 10 2 Structure determines enzymatic catalysis as illustrated by this mechanism for ____ 2015, September 8 PHRM 836 - Devlin Ch 10 www.studyblue.com 3 Substrate binding by enzymes • Highly complementary interac(ons between substrate and enzyme – Hydrophobic to hydrophobic – Hydrogen bonding – Favorable Coulombic interac(ons • Substrate binding typically involves some degree of conformaonal change in the enzyme – Enzymes need to be flexible for substrate binding and catalysis. – Provides op(mal recogni(on of substrates – Brings cataly(cally important residues to the right posi(on. 2015, September 8 PHRM 836 - Devlin Ch 10 4 Substrate binding by enzymes • Highly complementary interac(ons between substrate and enzyme – Hydrophobic to hydrophobic – Hydrogen bonding – Favorable Coulombic interac(ons • Substrate binding typically involves some degree of conformaonal change in the enzyme – Enzymes need to be flexible for substrate binding and catalysis. – Provides op(mal recogni(on of substrates – Brings cataly(cally important residues to the right posi(on.